Biofunctional self-assembled nanoparticles of folate-PEG-heparin/PBLA copolymers for targeted delivery of doxorubicin

被引:32
作者
Li, Li [1 ]
Huh, Kang Moo [1 ]
Lee, Yong-Kyu [2 ]
Kim, So Yeon [3 ]
机构
[1] Chungnam Natl Univ, Dept Polymer Sci & Engn, Taejon 305764, South Korea
[2] Chungju Natl Univ, Coll Adv Sci & Technol, Dept Chem & Biol Engn, Chungju 380702, South Korea
[3] Chungnam Natl Univ, Coll Educ, Dept Chem Engn Educ, Taejon 305764, South Korea
关键词
ENHANCED PERMEABILITY; TUMOR; ANTITUMOR; MICELLES; ANGIOGENESIS; DERIVATIVES; CONJUGATE; COMPLEX; SYSTEMS; DRUGS;
D O I
10.1039/c1jm11944c
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
To achieve a targeted drug delivery system for chemotherapy, we synthesized a ligand-mediated nanoparticulate drug carrier composed of folate-conjugated heparin-based copolymers. The use of a heparin-based drug delivery system is of special interest due to the attractive anticancer properties of heparin. Heparin-poly(beta-benzyl-L-aspartate) (HP) and folate-poly(ethylene glycol)-conjugated HP (FPHP) amphiphilic copolymers were synthesized for delivery of doxorubicin (DOX). DOX was effectively incorporated into HP and FPHP nanoparticles at a high loading content and efficiency by a simple dialysis method. The DOX-loaded HP and FPHP nanoparticles had average diameters of 86210 nm, depending on the drug loading content and the compositions of copolymers. Both DOX-loaded HP and FPHP nanoparticles had a sustained drug release pattern, and DOX-release from nanoparticles at pH 5.0 was much faster than that at pH 7.4. This pH-dependent DOX release property may ensure intracellular drug release due to decreases in pH values inside the endosomes and lysosomes of tumor cells. Furthermore, the DOX-loaded FPHP nanoparticles exhibited a greater extent of intracellular uptake against folate-receptor positive KB cells than DOX-loaded HP nanoparticles, indicating that the FPHP nanoparticles may serve as an effective active targeting carrier. The DOX-loaded FPHP nanoparticles also showed more potent cytotoxic effect on KB cells than on folate-receptor negative A549 cells. These results suggested that the FPHP nanoparticle is a promising candidate for targeted delivery of anticancer drugs to folate-receptor positive cells.
引用
收藏
页码:15288 / 15297
页数:10
相关论文
共 36 条
  • [1] Ligand based dendritic systems for tumor targeting
    Agarwal, Abhinav
    Saraf, Surbhi
    Asthana, Abhay
    Gupta, Umesh
    Gajbhiye, Virendra
    Jain, Narendra K.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 350 (1-2) : 3 - 13
  • [2] Nano-engineering block copolymer aggregates for drug delivery
    Allen, C
    Maysinger, D
    Eisenberg, A
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 1999, 16 (1-4) : 3 - 27
  • [3] AOYAMA T, 1987, CHEM PHARM BULL, V35, P808
  • [4] ENDOTHELIAL BINDING-SITES FOR HEPARIN - SPECIFICITY AND ROLE IN HEPARIN NEUTRALIZATION
    BARZU, T
    VANRIJN, JLML
    PETITOU, M
    MOLHO, P
    TOBELEM, G
    CAEN, JP
    [J]. BIOCHEMICAL JOURNAL, 1986, 238 (03) : 847 - 854
  • [5] Structural features of low-molecular-weight heparins affecting their affinity to antithrombin
    Bisio, Antonella
    Vecchietti, Davide
    Citterio, Laura
    Guerrini, Marco
    Raman, Rahul
    Bertini, Sabrina
    Eisele, Giorgio
    Naggi, Annamaria
    Sasisekharan, Ram
    Torri, Giangiacomo
    [J]. THROMBOSIS AND HAEMOSTASIS, 2009, 102 (05) : 865 - 873
  • [6] Antitumor and antimetastatic effect of warfarin and heparins
    Bobek, V
    Kovarík, J
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (04) : 213 - 219
  • [7] Non-Anticoagulant Heparins and Inhibition of Cancer
    Casu, Benito
    Vlodavsky, Israel
    Sanderson, Ralph D.
    [J]. PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2007, 36 (3-4) : 195 - 203
  • [8] Preparation of sodium deoxycholate (DOC) conjugated heparin derivatives for inhibition of angiogenesis and cancer cell growth
    Cho, Kwang Jae
    Moon, Hyun Tae
    Park, Go-Eun
    Jeon, Ok Chul
    Byun, Youngro
    Lee, Yong-Kyu
    [J]. BIOCONJUGATE CHEMISTRY, 2008, 19 (07) : 1346 - 1351
  • [9] De Wolf FA, 2000, PHARMACOL REV, V52, P207
  • [10] Duncan R, 1998, ANN ONCOL, V9, P39